Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Soligenix: Initiates New Programs To Target Melioidosis

(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)

I have been following Soligenix (OTCQB:SNGX) since last summer and am still a big fan of the company. One of the reasons I like SGNX is that management can executes its strategy very well. In my previous articles about SNGX, I talked about its multiple clinical and preclinical programs targeting various indications including oral mucositis, Crohn's disease, and biodefense vaccines.

In this article, I am going to discuss a specific program, melioidosis, in which Soligenix is making progress.

Soligenix Initiates development of SGX943 for Melioidosis

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details